期刊文献+

头孢丙烯分散片在Beagle犬体内的药动学和相对生物利用度研究 被引量:1

Study on in Vivo Pharmacokinetics and Relative Bioavailability of Cefprozil Dispersible Tablet in Beagle Dogs
下载PDF
导出
摘要 目的建立高效液相色谱(HPLC)法测定犬血浆中头孢丙烯的质量浓度,研究头孢丙烯分散片在Beagle犬体内的药动学和相对生物利用度。方法 12只Beagle犬双周期随机交叉单剂量口服500mg头孢丙烯分散片和普通片剂,洗净期为1周,采用HPLC法测定血浆中头孢丙烯的质量浓度。结果分散片与普通片的体内过程基本一致,其主要药代动力学参数峰浓度(Cmax)分别为(48.7±4.2)μg/mL和(51.1±3.3)μg/mL,达峰时间(Tmax)分别为(1.5±0.3)h和(2.0±0.4)h,半衰期(t1/2)分别为(1.2±0.3)h和(1.6±0.4)h,0~24h药-时曲线下面积(AUC0-24)分别为(188.9±27.5)μg/(h·mL)和(208.2±34.3)μg/(h·mL)。结论头孢丙烯分散片口服后吸收迅速,平均相对生物利用度为90.7%。 Objective To establish an HPLC method for the determination of cefprozil serum concentration and to study the in vivo pharmacokinetics and the relative bioavailability of Cefprozil Dispersible Tablet in Beagle dogs.Methods 12 Beagle dogs received the single oral dose of cefprozil 500 mg in dispersible tablets or common tablets with doublecycle randomized cross-over.The clearing period was 1 week. The cefprozil concentration was detected by HPLC.Results The intracorporal process of dispersible tablets was basically consistent with that of the common tablets.The main pharmacokinetic parameters were as follows:Cmax was (48.7±4.2)μg/mL and (51.1±3.3)μg/mL,Tmax was (1.5±0.3)h and (2.0±0.4)h,t1/2 was (1.2±0.3)h and (1.6±0.4)h,AUC0-24 was (188.9±27.5)μg/(h·mL) and (208.2±34.3)μg/(h·mL).Conclusion Cefprozil Dispersible Tablet is rapidly absorbed after oral administration with the average relative bioavailability of 90.7%.
出处 《中国药业》 CAS 2010年第11期6-7,共2页 China Pharmaceuticals
关键词 头孢丙烯 高效液相色谱法 相对生物利用度 cefprozil HPLC relative bioavailability
  • 相关文献

参考文献4

二级参考文献22

  • 1肖涛,张孝清,曹芳,田春梅,王锦堂.头孢丙烯的合成[J].中国医药工业杂志,2004,35(7):388-390. 被引量:13
  • 2张明发.头孢丙烯的抗菌药理与临床[J].上海医药,2005,26(3):111-117. 被引量:33
  • 3雷招宝.新的口服头孢菌素——头孢普齐[J].中国新药杂志,1994,3(5):24-26. 被引量:3
  • 4刘新宇,吴芳.头孢丙烯在下呼吸道细菌感染患者的药代动力学研究[J].药学实践杂志,2006,24(3):144-146. 被引量:5
  • 5Park TH, Kim JK, Jee JP, Park JS, Kim CK. HPLC method for simultaneous determination of cefprozil diastereomers in human plasma[J]. J Pharm Biomed Anal, 2004,36: 243 - 8.
  • 6Guay DRP.Cefdinir:An advanced—generation,broad—spectrum oral cephalosporin.Clin Ther,2002,24(1):473.
  • 7Wiseman LR, Benfield P. Cefprozil, A review of its antibacterial activity, pharmacokinefic properties, and therapeutic potential. Drugs, 1993,45 (2) :295.
  • 8Fung- Tome JC, Huezko Z, Stickle T, et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother, 1995,39 ( 2 ) : 533.
  • 9Barriere S L. Review of in vitro activity, pharmacokinetic characteristics, safety and efficacy of cefproil, a new oral cephalosporin [J]. Ann Pharmacother, 1993,27 : 1082-1089.
  • 10Barbhaiya R H,Shukla U A,Gleason C R,Shyu W C,Wilber R B,Martin R R,et al. Phase Ⅰ study of multiple-dose cefprozil and comparison with cefaclor[J]. Antimicrob Agents Chemother, 1990,34 : 1198-1203.

共引文献37

同被引文献5

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部